A Phase II study [43] is investigating treatment with cilofexor alone or in combination with Firsocostat (GS-0976), an acetyl-CoA carboxylase (ACC) inhibitor, and Selonsertib, an apoptosis signal-regulating kinase 1 (ASK-1) inhibitor, in patients with advanced fibrosis due to NASH. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.